Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025Cancer Immunology Research

Abstract B012: Bromodomain and extra-terminal domain (BET) as a therapeutic target in a mouse model of secondary hemophagocytic lymphohistiocytosis (HLH)

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPaola Martina MarraRKRathan KumarCMCharlene Mao

Discussion

Loading...

Member takes

Overview

Experimental analysis shows BET inhibitors reduce cytokine levels in a C57BL/6 HLH model, indicating therapeutic potential.

Key Points

  • BET inhibition leads to significant reductions in liver and spleen enlargement in HLH mice compared to controls.
  • OPN-51107 treatment resulted in a significant improvement of red blood cell counts, contrasting with vehicle-treated HLH mice.
  • Elevated plasma IFN-γ and IL-6 markers in vehicle-treated HLH mice were significantly lowered with BET inhibitor treatment.
  • Restoration of splenic T cell plasticity was observed after BET inhibition, suggesting reversal of immune dysregulation.

Cite This Study

Marra et al. (2025) studied this question.

synapsesocial.com/papers/68d5dabfddad3c16d4636ffchttps://doi.org/10.1158/2326-6074.cimm25-b012
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bromodomain and extra-terminal domain (BET) as a therapeutic target in a mouse model of secondary hemophagocytic lymphohistiocytosis (HLH)2025
  2. 2BET inhibition targets pathogenic interstitial macrophages to limit antibody mediated fibrosis in bronchiolitis obliterans chronic gvhd2025
  3. 3Tamoxifen-inducible Pld3 Pld4 knockout mouse model as an animal model for secondary HLH and its treatment 20272025
  4. 4A novel spontaneous HLH mouse model by engrafting human HSCs into b-ndg MGMT3 mice2025
  5. 5Unmasking HLH: A BCOR mutation as the hidden driver of immune dysregulation and fulminant hepatic failure2025